Related

Market position

RS presents itself as operating at the intersection of computational target selection, preclinical drug discovery and early-stage biotech investing, arguing that parallel advances in data science, biology, therapeutic modalities, discovery technologies and the contract research sector have created favorable conditions for drug creation. It notes that more than 10 new therapeutic modalities have been clinically validated over the past decade and that better drugs could be developed for over 5,000 untreated or underserved disease populations.

RS positions "integration as the innovation": combining an AI/ML opportunity-ranking platform, an investment model focused on preclinical discovery, decentralized team science and outsourced hub-and-spoke R&D rather than specializing in one technology, target or disease. It claims its decentralized, fully virtual operating model with shared back-office and a tax-efficient corporate structure reduces R&D cost structures by more than 40%, and that partnering with external discovery service providers on risk-sharing terms avoids the 40-60% of capital historically spent on building labs and hiring generalist staff.

Technology

The core technology is RS Facets, a proprietary machine learning platform described as ingesting activity across global biomedicine and predicting the best new drug discovery opportunities for each disease on a quantified and explainable basis. Facets is built on a three-layer architecture: a unified dataset covering all of biomedicine, a quantitative opportunity-ranking layer, and predictive AI/ML models. The company also describes reliance on growing human clinical and genetics datasets, large language and machine learning models, and externally available discovery technologies such as AI-enabled structural prediction, in silico screening and design, high-throughput robotics, and advanced compound libraries and screening methods.

Go-to-market

RS curates and partners with drug discovery service providers and contract research organizations to obtain centralized access to advanced R&D capabilities under preferred cost structures and risk-sharing agreements, and assembles large, multidisciplinary virtual teams spanning academia and industry to design R&D strategy. Its website maintains a Companies section and lists info@related.vc as its contact point.

Geography

The company lists an address at 1312 17th St PMB 76870, Denver, CO 80202, and operates as a fully virtual organization with globally distributed teams working across countries, research disciplines, vendors, academia and industry. It contrasts this with the concentration of US biotech venture capital, roughly 60-70% of which it says goes to just two states.